Spyre Therapeutics (SYRE) Exchange Rate Effect (2020 - 2024)
Spyre Therapeutics posted quarterly Exchange Rate Effect of -$15000.0 for Q4 2024, down 183.33% year-on-year from $18000.0 in Q1 2024, and down 193.75% on a QoQ basis from $16000.0 in Q3 2024.
Spyre Therapeutics (SYRE) has 5 years of Exchange Rate Effect data on file, last reported at -$15000.0 in Q4 2024.
- For the quarter ending Q4 2024, Exchange Rate Effect fell 183.33% year-over-year to -$15000.0; the trailing twelve-month figure through Sep 2025 stood at -$15000.0 (down 150.0% YoY), and the FY2024 full-year result was -$3000.0, down 112.0% from the prior year.
- Exchange Rate Effect for Q4 2024 stood at -$15000.0, down from $16000.0 in the prior quarter.
- Across five years, Exchange Rate Effect topped out at $47000.0 in Q4 2020 and bottomed at -$72000.0 in Q2 2022.
- The 5-year median for Exchange Rate Effect is $3500.0 (2021), against an average of -$3250.0.
- Peak annual rise in Exchange Rate Effect reached 1433.33% in 2022, while the deepest fall reached 1900.0% in 2022.
- A 5-year view of Exchange Rate Effect shows it stood at $47000.0 in 2020, then sank by 93.62% to $3000.0 in 2021, then soared by 1433.33% to $46000.0 in 2022, then tumbled by 60.87% to $18000.0 in 2023, then slumped by 183.33% to -$15000.0 in 2024.
- The last three Exchange Rate Effect figures came in at -$15000.0 (Q4 2024), $16000.0 (Q3 2024), and -$4000.0 (Q1 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Exchange Rate Effect (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 3.60 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -2.70 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | -40.30 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -900,000.00 |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -7.06 Mn |
| 10 | Spyre Therapeutics | 5.55 Bn | 5.55 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -15,000.00 |
| Dec 31, 2024 | -15,000.00 |
| Sep 30, 2024 | 16,000.00 |
| Sep 30, 2024 | 16,000.00 |
| Mar 31, 2024 | -4,000.00 |
| Mar 31, 2024 | -4,000.00 |
| Dec 31, 2023 | 18,000.00 |
| Dec 31, 2023 | 18,000.00 |
| Sep 30, 2023 | -17,000.00 |
| Sep 30, 2023 | -17,000.00 |
| Jun 30, 2023 | 13,000.00 |
| Jun 30, 2023 | 13,000.00 |
| Mar 31, 2023 | 11,000.00 |
| Mar 31, 2023 | 11,000.00 |
| Dec 31, 2022 | 46,000.00 |
| Dec 31, 2022 | 46,000.00 |
| Sep 30, 2022 | -57,000.00 |
| Sep 30, 2022 | -57,000.00 |
| Jun 30, 2022 | -72,000.00 |
| Jun 30, 2022 | -72,000.00 |
| Mar 31, 2022 | -23,000.00 |
| Mar 31, 2022 | -23,000.00 |
| Dec 31, 2021 | 3,000.00 |
| Dec 31, 2021 | 3,000.00 |
| Sep 30, 2021 | -29,000.00 |
| Sep 30, 2021 | -29,000.00 |
| Jun 30, 2021 | 4,000.00 |
| Jun 30, 2021 | 4,000.00 |
| Mar 31, 2021 | 7,000.00 |
| Mar 31, 2021 | 7,000.00 |
| Dec 31, 2020 | 47,000.00 |
| Dec 31, 2020 | 47,000.00 |